Ellis Levine

MD
Medical Oncology
Buffalo Spree Top Doctor 2024

Dr. Levine is a Buffalo Spree Top Doctor! See all of our physicians who made this year's list.

Top Doctors 2024

Cancers Treated:

Breast Penile Prostate Testicular Urethral

Research Interests:

Novel therapies for breast and urothelial cancer

About Ellis Levine

Positions

Roswell Park Comprehensive Cancer Center
  • Professor of Oncology
  • Chief, Breast Medicine
  • Hematology/Medical Oncology Fellowship Director
  • Department of Medicine

Jacobs School of Medicine and Biomedical Sciences, University at Buffalo

  • Professor of Medicine
  • Director, Hematology/Medical Oncology Fellowship Program

Background

Education and Training:

  • MD - University of Pittsburgh, Pittsburgh, PA

Residency:

  • University of Minnesota, Minneapolis, MN

Fellowship:

  • University of Minnesota, Minneapolis, MN

Board Certification:

  • Internal Medicine, American Board of Internal Medicine
  • Medical Oncology, American Board of Internal Medicine

Honors & Awards:

  • 2005-2023 - America’s Top Doctors
  • 2018 - Susan G. Komen Hope Award for Upstate New York
Palbociclib and Binimetinib in RAS-Mutant Cancers, A ComboMATCH Treatment Trial
Learn More
Study of Chemotherapy Plus Ipatasertib for People With Solid Tumors With AKT Mutations, A ComboMATCH Treatment Trial
Learn More
Testing the Role of FDG-PET/CT to Predict Response to Therapy Prior to Surgery for HER2-positive Breast Cancer, The DIRECT Trial
Learn More
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Learn More
Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial
Learn More
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
Learn More
Abemaciclib and Endocrine Therapy in Older Patients With Breast Cancer.
Learn More
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
Learn More
Accelerated v's Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumours
Learn More
T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial
Learn More

Clinical Trials

Palbociclib and Binimetinib in RAS-Mutant Cancers, A ComboMATCH Treatment Trial
Learn More
Study of Chemotherapy Plus Ipatasertib for People With Solid Tumors With AKT Mutations, A ComboMATCH Treatment Trial
Learn More
Testing the Role of FDG-PET/CT to Predict Response to Therapy Prior to Surgery for HER2-positive Breast Cancer, The DIRECT Trial
Learn More
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Learn More
Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial
Learn More
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
Learn More
Abemaciclib and Endocrine Therapy in Older Patients With Breast Cancer.
Learn More
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
Learn More
Accelerated v's Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumours
Learn More
T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial
Learn More

Featured on Cancer Talk

ER-positive breast cancer: Edith’s story
Triple-positive breast cancer: Jennifer’s story
Stage 2 male breast cancer: Jim’s story

Showing all3 of 12

Publications

Full Publications list on PubMed

Alaklabi S, Roy AM, Attwood K, George A, O'Connor T, Early A, Levine EG, Gandhi S. Real world outcomes with alpelisib in metastatic hormone receptor-positive breast cancer patients: A single institution experience. Front Oncol. 2022 Oct 20;12:1012391. doi: 10.3389/fonc.2022.1012391. PMID: 36338738; PMCID: PMC9631302.

Gandhi S, Opyrchal M, Grimm MJ, Slomba RT, Kokolus KM, Witkiewicz A, Attwood KM, Groman A, Williams l, Tarquini ML, Wallace PK, Soh KT, Minderman H, Mcguire O, O’Connor TL, Early AP, Levine EG, Kalinski P (2022) Systemic IFN-a/TLR3-Ligand Combination Reprograms Local Microenvironments of Breast Cancer Lesions for Selective CTL Influx. Journal for ImmunoTherapy of Cancer 2023;11:e007381. doi: 10.1136/jitc-2023-007381

Ademuyiwa FO, Northfelt DW, O'Connor T, Levine E, Luo J, Tao Y, Hoog J, Laury ML, Summa T, Hammerschmidt T, Guo Z, Frith A, Weilbaecher K, Opyrchal M, Aft R, Clifton K, Suresh R, Bagegni N, Hagemann IS, Iglesia MD, Ma CX. A phase II study of palbociclib plus letrozole plus trastuzumab as neoadjuvant treatment for clinical stages II and III ER+ HER2+ breast cancer (PALTAN). NPJ Breast Cancer. 2023 Jan 6;9(1):1. doi: 10.1038/s41523-022-00504-z. PMID: 36609389; PMCID: PMC9822956.

Abraham A, Barcenas CH, Bleicher RJ, Cohen AL, Javid SH, Levine EG, Lin NU, Moy B, Niland JC, Wolff AC, Hassett MJ, Asad S, Stover DG. Clinicopathologic and sociodemographic factors associated with late relapse triple negative breast cancer in a multivariable logistic model: A multi-institution cohort study. Breast. 2023 Feb;67:89-93. doi: 10.1016/j.breast.2023.01.004. Epub 2023 Jan 17. PMID: 36681001.

Witkiewicz AK, Schultz E, Wang J, Hamilton D, Levine E, O'Connor T, Knudsen ES. Determinants of response to CDK4/6 inhibitors in the real-world setting. NPJ Precis Oncol. 2023 Sep 13;7(1):90. doi: 10.1038/s41698-023-00438-0. PMID: 37704753; PMCID: PMC10499925.

Witkiewicz AK, Wang J, Schultz E, O’Connor TN, O’Connor T, Levine E, Knudsen E. Developing Algorithms to Predict the Duration of Response to CDK 4/6 Inhibitor-Based Therapy in Metastatic HR+/HER2- Breast Cancer. submitted